Literature DB >> 3925430

Evaluation of two tetravalent (ACYW135) meningococcal vaccines in infants and small children: a clinical study comparing immunogenicity of O-acetyl-negative and O-acetyl-positive group C polysaccharides.

H Peltola, A Safary, H Käyhty, V Karanko, F E André.   

Abstract

Two different tetravalent polysaccharide vaccines against group A, C, Y, and W135 meningococci were given to 118 infants aged 6 to 23 months; the same vaccines were administered in a second dose 12 months later to those infants aged 6 to 11 months at first vaccination. Forty of the infants received vaccine containing the nonacetylated group C polysaccharide C(OAc-) and 78 the acetylated group C polysaccharide C(OAc+) together with group A, Y, and W135 polysaccharides. All polysaccharides, at a dose of 30 micrograms, induced antibody responses after administration of both vaccines in all age groups although the responses were better in the older infants. Acetylation of the sialic acid of the group C polysaccharide did not significantly influence the response. Rapid decreases in the antibody titers after the first vaccination stressed the need for one or more revaccinations. Vaccination elicited mild local and systemic reactions. Elevated temperatures were more common in the youngest infants but only four developed fever exceeding 38.5 degrees C (101.3 degrees F). We conclude that tetravalent (ACYW135) meningococcal vaccine is safe and immunologically effective in children younger than age 2 years. However, revaccinations may be required to maintain immunity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3925430

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  22 in total

1.  Analysis of human serum immunoglobulin G against O-acetyl-positive and O-acetyl-negative serogroup W135 meningococcal capsular polysaccharide.

Authors:  Peter C Giardina; Emma Longworth; Renee E Evans-Johnson; Michaelene L Bessette; Hong Zhang; Ray Borrow; Dace Madore; Philip Fernsten
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

2.  Meningococcal group C and w135 immunological hyporesponsiveness in african toddlers.

Authors:  Helen Findlow; Samba Sow; Ray Borrow; Milagritos Tapia; Fadima Cheick Haidara; Adebayo K Akinsola; Olubukola T Idoko; Fatoumata Diallo; Richard Adegbola; Yuxiao Tang; Varsha Parulekar; Helen Chadha; Lesley Mabey; Daniel Holme; Kelly Townsend; Julie Chaumont; F Marc Laforce; Prasad S Kulkarni; Elisa Marchetti; Simonetta Viviani; Musa Hassan-King; Marie-Pierre Preziosi
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

3.  Conjugates of group A and W135 capsular polysaccharides of neisseria meningitidis bound to recombinant Staphylococcus aureus enterotoxin C1: preparation, physicochemical characterization, and immunological properties in mice.

Authors:  Zhigang Jin; Gregory A Bohach; Joseph Shiloach; Scott E Norris; Darón I Freedberg; Claudia Deobald; Bruce Coxon; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  One Flu Over the Cuckoo's Nest.

Authors:  H Seiden
Journal:  Can Fam Physician       Date:  1987-02       Impact factor: 3.275

5.  Vol au-dessus d'un nid de coucous.

Authors:  H Seiden
Journal:  Can Fam Physician       Date:  1987-03       Impact factor: 3.275

6.  Isolation of Neisseria meningitidis mutants deficient in class 1 (porA) and class 3 (porB) outer membrane proteins.

Authors:  J Tommassen; P Vermeij; M Struyvé; R Benz; J T Poolman
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

Review 7.  Vaccines for prevention of meningococcal disease.

Authors:  C E Frasch
Journal:  Clin Microbiol Rev       Date:  1989-04       Impact factor: 26.132

8.  Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.

Authors:  C T Sacchi; A P Lemos; T Popovic; J C De Morais; A M Whitney; C E Melles; L M Brondi; L M Monteiro; M V Paiva; C A Solari; L W Mayer
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

9.  Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.

Authors:  E Rosenqvist; E A Høiby; E Wedege; K Bryn; J Kolberg; A Klem; E Rønnild; G Bjune; H Nøkleby
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

Review 10.  Meningococcal lipopolysaccharides: virulence factor and potential vaccine component.

Authors:  A F Verheul; H Snippe; J T Poolman
Journal:  Microbiol Rev       Date:  1993-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.